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Variations in in viva phosphorylation at the proline-rich domain of the
microtubule-associated protein 2 (MAP2) during rat brain development
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Microtubule-associated protein 2 (MAP2) is an in vitro substrate
for MAP kinase. Part of the phosphorylation occurs at the C-
terminal microtubule-binding domain of the molecule which
contains a cluster of putative consensus sites for MAP kinase on
a proline-rich region. A peptide with the sequence RTPGTPG-
TPSY, located at this region of the molecule, is efficiently
phosphorylated by MAP kinase in vitro. An antibody (972)
raised against this non-phosphorylated peptide has been used to
test for in vivo phosphorylation at the proline-rich domain of the
MAP2 molecule. The reaction of purified MAP2 with antibody
INTRODUCTION
Microtubule-associated protein 2 (MAP2) is a major component
of the neuronal cytoskeleton [1-3]. In mammalian brain, there
are several forms of MAP2 that arise from alternative splicing
[3,4]. These include high-molecular-mass proteins known as
MAP2A and MAP2B (with apparent molecular masses around
270 kDa determined by denaturing gel electrophoresis [5]) and
low-molecular-mass forms referred to as MAP2C and MAP2D
(with apparent molecular masses around 70 kDa determined by
denaturing gel electrophoresis [6,7]). MAP2C consists of the
N- and C-terminal domains of MAP2A/B joined together and
lacking the middle intervening sequence. The C-terminal segment
of the molecule contains a proline-rich region followed by three
or four conserved microtubule-binding sequences [5-7].
MAP2C is expressed in developing mammalian brain and
it is down-regulated during brain maturation, whereas
MAP2A/B is more prominent in the adult brain [3]. MAP2C has
a widespread distribution in brain, being present in neuronal cell
bodies, dendrites and axons as well as in glial cells [3]. In
contrast, MAP2A/B is selectively localized in dendrites and
neuronal cell bodies [3,8-10]. In addition to its association with
microtubules, MAP2 is co-localized with actin and associated
with actin microfilaments, membrane organelles and the post-
synaptic density in dendritic spines [11,12].
MAP2A/B (simply referred to as MAP2) is one of the best in
vitro substrates for a variety of protein kinases [13-19] and
phosphatases [20,21]. Extensive in vitro phosphorylation of
MAP2 favours microtubule disassembly [13,22-24]. In fact, a
fraction ofMAP2 isolated from adult rat brain contains up to 46
phosphates per molecule and binds less efficiently to microtubules
than another fraction of MAP2 which contains 16 phosphates
per molecule [25]. However, completely dephosphorylated MAP2
cannot efficiently interact with microtubules [26]. Phosphoryl-
972 diminishes after in vitro phosphorylation by MAP kinase
and is enhanced after in vitro dephosphorylation by alkaline
phosphatase. A fraction ofbrain MAP2 isolated by iron-chelation
affinity chromatography appears to be phosphorylated in vivo at
the site recognized by antibody 972. There is some variation
in the phosphorylation of MAP2 at the proline-rich region
throughout rat brain development. MAP2C is more highly
phosphorylated in the developing rat brain, whereas high-
molecular-mass MAP2 is more extensively phosphorylated in the
adult rat brain.
ation also controls the association of MAP2 with actin
microfilaments [27,28].
Interestingly, a correlation between the phosphorylation state
of MAP2 and several forms of neuronal plasticity has been
noticed, leading to the proposal of a physiological role for MAP2
phosphorylation and dephosphorylation in triggering cyto-
skeletal changes in response to certain extracellular signals
[29-34]. It is, however, extremely difficult to observe in vivo
subcellular and molecular events that may be linked to adaptative
changes in brain. The development of reagents such as antibodies
that can discriminate between distinct phosphorylated forms of
a protein may be useful in this respect. Here we have focused on
the phosphorylation ofMAP2 at the proline-rich region of the C-
terminal domain of the molecule. This domain contains eight
Pro-X-Ser/Thr-Pro motifs which may be targets forMAP kinases
in vitro. One of these sites has been used to raise a monospecific
polyclonal antibody that binds to MAP2 in a phosphorylation-
sensitive manner. Using this immunochemical approach we have
analysed the in vivo phosphorylation of MAP2 in rat brain
extracts at three developmental stages: embryonic day 19,
postnatal day 1 and postnatal day 21.
MATERIALS AND METHODS
Protein preparation
Brains were obtained from cows or Wistar rats of different ages.
To prepare MAP2, brains were homogenized in 0.1 M Mes,
pH 6.5, containing 1 mM MgCl2, 2 mM EGTA, 0.1 M NaCl,
1 mM phenylmethanesulphonyl fluoride (PMSF), 10 ,tg/ml pep-
statin, 10 ,tg/ml leupeptin and 10 ,ug/ml aprotinin (in some cases,
homogenization was performed in the presence of 1 ,uM okadaic
acid and 50 mM NaF as phosphatase inhibitors). Homogenates
were centrifuged at 100000 g for 1 h at 2 'C. Pellets were
Abbreviations used: MAP2, microtubule-associated protein 2; PMSF, phenylmethanesulphonyl fluoride; DTT, dithiothreitol; i.c.a.c., iron chelation
affinity chromatography.
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discarded and the supernatants (brain cytosolic fractions) were
collected. In some cases, supernatant were treated with alkaline
phosphatase (see below). Brain cytosolic fractions were brought
to 1 M NaCl and 10 mM dithiothreitol (DTT), boiled for 10 min
and centrifuged at 100000 g for 30 min at 2 'C. Heat-resistant
proteins present in the resulting supernatants were used as a
source for MAP2 purification.
Heat-resistant cytosolic proteins were applied to a Sepharose
CL-4B (Pharmacia) column (40 ml) previously equilibrated with
buffer (10 mM Pipes, pH 6.9, 0.2 M NaCl and 1 mM DTT).
Purified MAP2A/B was eluted as one of the first peaks from this
column as previously described by Herzog and Weber [35].
Microtubule protein from brain cytosol was prepared by the
procedure of Karr et al. [36].
The peptide P with the sequence RTPGTPGTPSY (comprising
residues 1616-1626 ofMAP2 according to the sequence published
by Lewis et al. [5]) was synthesized on an automatic solid-phase
peptide synthesizer (type A430A; Applied Biosystems) and
purified by reversed-phase h.p.l.c. on a Nova Pak C18 column
(Waters). The corresponding phosphorylated peptide was
obtained by solid-phase phosphorylation and oxidation [37].
Purified MAP kinase (p44mapk, ERK1) was purchased from
UBI (Lake Placid, NY, U.S.A.; Cat. no. 14-102).
Antibodies
Polyclonal antibody 972 was raised in rabbit against the synthetic
peptide P (see above) coupled to keyhole limpet haemocyanin
using glutaraldehyde as cross-linker. Peptide coupling and
immunization were performed as described by Ulloa et al. [38].
Immunoglobulins were purified from sera by (NH4)2SO4 pre-
cipitation. The specific reaction of antibody 972 with the P
peptide was checked by dot-blot and competition assays as
indicated by Ulloa et al. [38]. Polyclonal antibody 10 was raised
in a mouse immunized with purified rat brain MAP2. The
specificity of the reaction was checked by an immunoblotting
assay. It recognizes mainly MAP2A/B. Rabbit polyclonal anti-
body 660, raised against bovine brain MAP2, was also used to
recognize MAP2A/B and MAP2C. Monoclonal antibody
MPM2, which binds to a phosphothreonine-proline-containing
epitode [39], was the generous gift of Dr. J. Kuang and Dr. P. N.
Rao (MD Anderson Cancer Center, Houston, TX, U.S.A.).
Protein and peptide phosphorylation
The phosphorylation of purified MAP2 (10 ,ug) with MAP kinase
(40 ng of a preparation which transfers 0.6 nmol of phosphate/
min and 1 mg of kinase into myelin basic protein) was performed
for 4 h at 37 'C in 20 mM Hepes, pH 7.4, containing 2 mM
EGTA, 10 mM MgCl2, 1 mM PMSF, 1 mM DTT, 10 ug/ml
pepstatin, 10 jug/ml leupeptin, 10 ,ug/ml aprotinin, 2 ,uM okadaic
acid and 100 ,uM [y-32P]ATP (Amersham). Phosphorylation was
stopped by the addition of SDS sample electrophoresis buffer.
Phosphorylated protein was analysed by SDS/PAGE and auto-
radiography of dried gels exposed to Kodak X-Omat films. To
determine the stoichiometry of phosphorylation of MAP2, the
phosphorylation assays were performed at increasing ATP con-
centrations and counts incorporated into MAP2 were deter-
mined,.
Phosphorylation of the P peptide by MAP kinase was carried
out in the same buffer as was used for MAP2 protein.
Phosphorylation was stopped by boiling for 2 min in the presence
of 1% trifluoroacetic acid. Phosphorylated peptide was isolated
by reversed-phase h.p.l.c. on a Nova Pak C18 column and the
radioactivity associated with the eluted peptide was determined
Phosphatase treatment
Samples (50 sg of protein) were incubated with 3.2 units of
alkaline phosphatase (Boehringer-Mannheim GmbH; cat. no.
1097 075) in dephosphorylation buffer containing 50 mM MgCl2,
100 mM Tris/HCl pH 8.5, 1 mM PMSF, 10 ,tg/ml pepstatin,
10 ,g/ml leupeptin and 10 ,g/ml aprotinin for 2 h at 37 'C.
After dephosphorylation, samples were brought to 1 M NaCl and
10 mM DTT, boiled for 5 min and centrifuged at 100000 g for
15 min. Supernatants containing dephosphorylated heat-resistant
proteins were collected.
Limited proteolysis of MAP2
Purified MAP2, previously phosphorylated in vitro by MAP
kinase, was partially digested with Staphylococcus aureus V8
protease as previously described [30,40]. Phosphopeptides were
analysed by gel electrophoresis and autoradiography of dried
gels on to Kodak X-Omat films. Among the resulting
phosphopeptides, the 54 kDa peptide was eluted from the gel
and sequenced with an Applied Biosystems gas-phase sequenator
(model 470A) equipped with an on-line phenylthiohydantoin
amino acid analyser (model 120A). Alternatively, peptides de-
rived from digested MAP2 were analysed by Western blotting.
Iron-chelation affinity chromatography (i.c.a.c.)
Columns (100 ll) were prepared with chelating Sepharose Fast
Flow (Pharmacia Fine Chemicals, Uppsala, Sweden) [41,42].
Briefly, the gel bed was washed with 4 vol. of water, treated with
4 vol. of 50 mM FeCl3 and washed again with water. The column
was then equilibrated in binding buffer (0.1 M Mes, 0.2 M NaCl
and 1 mM DTT, pH 5.7). Purified MAP2 (200-300 4ug) was
loaded on to the i.c.a.c. column, which was washed with binding
buffer and eluted by a stepwise pH gradient composed of the
following solutions: 100 mM Tris/HCl, 1 M NaCl and 1 mM
DTT at pH 7.8, pH 8.0, pH 8.4 and 8.6. The most strongly
bound protein and the chelated iron were eluted by washing with
200 mM EDTA. Collected fraction were analysed by electro-
phoresis.
Electrophoresis
SDS/PAGE was carried out by the procedure of Laemmli [43]
on 5 % or 8 % polyacrylamide gels. Gels were stained with either
Coomassie Brilliant Blue or imidazole/zinc salts [44]. Gel
densitometry was performed on a Molecular Dynamics den-
sitometer model 300A equipped with Image Quant software
version 3.0.
Western-blot analysis was performed by the method of
Towbin et al. [45]. To test for antibody reaction, the ECL
Amersham kit was used. Autoradiograms were also quantified
by densitometry as described above.
RESULTS AND DISCUSSION
In vitro phosphorylation of MAP2 by MAP kinase
Incubation of purified bovine brain MAP2 with pure MAP
kinase p44mapl ERKI) results in modification of the protein as
shown in Figure l(a). In the presence of 1 mM ATP and after
4 h of incubation at 37 'C, nearly 6 mol of phosphate/mol of
MAP2 are incorporated (Figure lb). This phosphorylation
stoichiometry is very similar to that previously described by
Hoshi et al. [13]. A higher phosphorylation stoichiometry is
observed when phosphatase-treated MAP2 is used as substrate,
by Cerenkov radiation counting. indicating that some phosphorylation sites are endogeneously
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Figure 1 In vitro phosphorylation of MAP2 by MAP kinase
(a) Purified bovine brain MAP2 (10 /ug) was incubated for 30 min with MAP kinase (40 ng of
a preparation which transfers 0.6 nmol of phosphate/min and 1 mg of kinase into myelin basic
protein) and 100,uM [y-32P]ATP as indicated in the Materials and methods section.
Phosphorylated protein was characterized by SDS/PAGE, followed by autoradiography of dried
gels exposed to Kodak X-Omat films. Lane 1, Coomassie Blue staining of the gel; lane 2,
corresponding autoradiogram. (b) Purified bovine brain MAP2 (10 ,ug) was incubated for 4 h
with p44 MAP kinase (40 ng) and increasing concentrations of [y-32P]ATP: 1 ,M, 10 ,M,
100 #M, 0.5 mM and 1 mM. Phosphate incorporation into protein was measured. The
maximum incorporation was nearly 6 mol of phosphate/mol of MAP2.
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Figure 2 Phosphopeptide pattern of in vitro phosphorylated MAP2
Purified bovine brain MAP2, previously phosphorylated with MAP kinase, was partially digested
with S. aureus V8 protease. Phosphopeptides were analysed by gel electrophoresis and
autoradiography (a). The positions of prestained molecular-mass standards (Sigma) are
indicated on the left. (b) Presumed localization of the major 54 and 42 kDa phosphopeptides
(marked with asterisks in a) on the MAP2 molecule according to the scheme proposed by Dfaz-
Nido et al. [30]. The three squares correspond to the three tubulin-binding motifs of the MAP2
molecule. The sequence determined for the N-terminus of the 54 kDa phosphopeptide is also
shown.
phosphorylated in purified brain MAP2, as previously suggested
[13,25,26].
Figure 3 In vitro phosphorylation of P peptide by MAP kinase
(a) Effect of substrate concentration on the incorporation of phosphate into P peptide catalysed
by MAP kinase. Different concentrations of P peptide were incubated with MAP kinase in the
presence of 0.1 mM [y-32P]ATP for 20 min at 37 OC. The reaction was stopped and the
incorporation of phosphate into peptide was determined as indicated in the Materials and
methods section. (b) Double-reciprocal plot for the determination of Km and Vm,ax for the
phosphorylation of P peptide by MAP kinase. The Km and Vmax values obtained are 2 mM and
500 ,umol/min per mg respectively.
binding domain of the MAP2 molecule [30,46] as indicated in
Figure 2(b). Indeed, the 54 kDa phosphopeptide is located at the
C-terminal region of the MAP2 molecule, as its N-terminal
sequence is LAKKSE, which corresponds to residues 1475-1480
of the MAP2 molecule. This result agrees well with a previous
determination of the sequence of the in vivo phosphorylated
54 kDa phosphopeptide derived from MAP2 (J. Diez-Guerra,
unpublished work).
Silliman and Sturgill [14] reported that the C-terminal micro-
tubule-binding domain of MAP2 was scarcely phosphorylated,
whereas Hoshi et al. [13] found a significant phosphorylation of
this MAP2 domain. Our results agree well with those reported by
Hoshi et al. [13]. Perhaps the discrepancies between these results
and those of Silliman and Sturgill [14] may be due to the presence
of different levels of endogenous phosphate in different MAP2
preparations.
The MAP2 molecule contains 18 (Pro)-X-Ser/Thr-Pro motifs
which may be considered putative targets for proline-directed
protein kinases, particularly MAP kinases, according to the
substrate specificity of these enzymes [46-48]. Eight of these
motifs are clustered in the C-terminal region of MAP2.
Interestingly, one of these sites has the sequence TPGTPGTPSY
(comprising residues 1617-1626 of the MAP2 sequence) which is
very similar to the sequence SPGSPGTPGS (comprising residues
199-208 of the tau sequence) found at the proline-rich region of
the microtubule-associated tau protein [49]. This peptide on tau
protein can be phosphorylated in vitro by proline-directed kinases
including MAP kinases [49]. In the same way, the synthetic
peptide referred to as P is efficiently phosphorylated in vitro by
purified MAP kinase. Figure 3 shows the apparent Km (2 mM)
and V',,ax (500 ,mol/min per mg) of the phosphorylation of P
peptide by MAP kinase. These values are similar to those
reported for the synthetic peptide with the sequence corre-
sponding to the site on myelin basic protein that is
phosphorylated by MAP kinase [46].
Localization of modified residues
Limited proteolysis by S. aureus V8 protease of purified bovine
brain MAP2 previously phosphorylated in vitro with MAP
kinase generates several phosphopeptides (Figure 2a). The two
largest, with apparent molecular masses of 54 kDa and 42 kDa,
are marked with asterisks in Figure 2(a); these phosphopeptides
may be derived from the region containing the microtubule-
Characterization of antibody 972 raised against the P peptide
Antibodies to non-phosphorylated synthetic peptides can be
used to test for the phosphorylation state of these sequences on
their corresponding native proteins [38,50,51]. Thus a polyclonal
rabbit antibody (972) was raised to the synthetic P peptide as
indicated in the Materials and methods section.
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Figure 4 Characterization of the binding of the rabbit polyclonal antibody 972 to MAP2
(a) Reaction of antibody 972 with MAP2 by Western blotting. Adult rat brain microtubule preparation (10 ,ug) was subjected to PAGE and either stained with imidazole/zinc (lane 1) or transferred
to nitrocellulose. Nitrocellulose paper was incubated with antibody 972 (at a 1:100000 dilution) and a peroxidase-conjugated secondary antibody. Antibody binding was detected with the ECL
Amersham kit and autoradiography. The autoradiogram is shown in lane 2. (b) Competition assay between MAP2 and synthetic P peptide for 972 binding. Samples of 1, 10 and 100 ,M non-
phosphorylated P peptide (0) or corresponding phosphorylated peptide (0) were incubated overnight with antibody 972 diluted 1:100000. These samples were then incubated with 50 ng of
purified bovine brain MAP2 previously dotted on to nitrocellulose paper. Control experiments in which antibody 972 was incubated without any peptide were also included. Antibody binding to
MAP2 was detected with the ECL Amersham kit and autoradiography. Autoradiograms were quantified by densitometry. The results are means + S.D. from three experiments. (c) Reaction of antibody
972 with V8 peptides from MAP2. Purified bovine brain MAP2 was partially digested with S. aureaus V8 protease (as described in the Materials and methods section and in the legend to Figure
2). The binding of antibody 972 to the resulting proteolytic peptides was assayed by Western blot. The autoradiogram shows the reaction of the 54 and 42 kDa MAP2 peptides with antibody 972.
(b) to MAP2 (Figure 4b). These results suggest that antibody 972 has
10 MPM2 972 a higher affinity for the non-phosphorylated peptide than for the
phosphorylated peptide.
The reaction of antibody 972 with the proteolytic peptides
SI1 * W derived from the partial digestion of purified bovine brain MAP2
with S. aureaus V8 protease has also been checked by Western-
blot assay (Figure 4c). Specific reaction of antibody 972 with the
above-mentioned 54 and 42 kDa proteolytic peptides is observed.
+
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Figure 5 Decreased binding of antibody 972 to in vitro phosphorylated
MAP2
Purified rat brain MAP2 was phosphorylated with MAP kinase in vitro as indicated in the
Materials and methods section. The reactions of purified MAP2 and in vitro phosphorylated
MAP2 with antibody 972 were compared by Western-blot assay. (a) Imidazole/zinc staining of
gel lanes containing purified MAP2 (-) and in vitro phosphorylated MAP2 (+). (b) Auto-
radiograms of the Western blots of purified MAP2 (-) and in vitro phosphorylated MAP2
(+) incubated with antibodies 10, MPM2 and 972. Antibody 10 reacts with MAP2
independently of its phosphorylation. Antibody MPM2 reacts more strongly with MAP kinase-
phosphorylated MAP2 and antibody 972 reacts more strongly with non-phosphorylated MAP2.
Antibody 972 specifically recognizes MAP2 in a bovine brain
microtubule protein preparation by Western-blot assay (Figure
4a). The reaction of antibody 972 with purified bovine brain
MAP2 in a dot-blot assay is effectively prevented by pre-
incubation of the antibody with increasing amounts of the non-
phosphorylated synthetic P peptide (Figure 4b, open circles).
Preincubation with the corresponding phosphopeptide (obtained
by phosphorylation and oxidation) is much less efficient at
inhibiting the binding of antibody 972 to MAP2 (Figure 4b,
closed circles) than preincubation with the non-phosphorylated
peptide. Thus 100,#M phosphopeptide is less inhibitory than
1 ,uM non-phosphorylated peptide of the binding of antibody 972
In order to analyse whether antibody 972 can discriminate
between MAP2 molecules with different degrees of
phosphorylation, purified MAP2 was phosphorylated in vitro
with p44 MAPK kinase. Figure 5 shows that antibody 972 shows
weaker binding to in vitro phosphorylated MAP2 than to non-
phosphorylated MAP2. As controls, an antibody that recognizes
MAP2 independently of its phosphorylation state (antibody 10)
and another antibody that only binds to phosphorylated MAP2
(monoclonal antibody MPM2) were tested in parallel. The
specific reaction of MAP kinase-phosphorylated MAP2 with
antibody MPM2 has been previously described [52].
MAP2 appears to be phosphorylated by p44 MAP kinase in
vitro at the site recognized by antibody 972, and this phos-
phorylation dimishes the affinity of this antibody for MAP2.
To investigate the interaction of antibody 972 with MAP2
molecules phosphorylated to different extents, purified brain
MAP2 was subfractionated by elution at increasing pH values
using i.c.a.c.. Ferric ions complexed on chelating agarose
selectively adsorb phosphoproteins. The greater the degree of
phosphorylation of the protein, the stronger the interaction with
the chelated iron, and a buffer with a more basic pH is required
to elute the protein from the iron-chelated agarose [41,42].
Figure 6(a) (upper panel) shows the subfractionation of adult
rat brain MAP2 by i.c.a.c. Only a small fraction of MAP2 is
(a)
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Figure 6 Decreased binding of antibody 972 to highly phosphorylated Figure 7 Developmental changes In the immunoreactivity of rat brain
MAP2 isolated from brain MAP2 with antibody 972
MAP2 was subfractionated according to its degree of phosphorylation by the procedure of
Garcia de Ancos et al. [42]. Purified rat brain MAP2 (200-300 ,ug) was loaded on to an i.c.a.c.
column previously equilibrated in 0.1 M Mes, containing 0.2 M NaCI and 1 mM DTT, and
eluted by a stepwise pH gradient with buffer containing 0.1 M Tris/HCI, 1 M NaCI and 1 mM
DTT at pH 7.8, 8.0, 8.2, 8.4, 8.6. The chelated iron was eluted with 200 mM EDTA. (a) Elution
profile of the protein in the absence (-AP) and presence (+AP) of phosphatase treatment.
(b) Reaction of antibodies 10 and 972 with portions of the fractions eluted at pH 7.8 and with
EDTA as tested by Western-blot assay.
Heat-resistant cytosolic proteins from embryonic day 19 (E19), postnatal day 1 (P1) and
postnatal day 21 (P21) rat brains were either left untreated (-) or treated (+) with alkaline
phosphatase. Portions of these samples containing 10 tg of total protein were subjected to
PAGE, electroblofted on to a nitrocellulose sheet and probed with antibody 972. The positions
of MAP2A/B and MAP2C are indicated on the left. Rabbit polyclonal antibody 660 was used
as a control (C).
eluted by washing the column at pH 5.7 and 7.8. At pH 8.0-8.4,
most MAP2 is eluted from the column. A small amount of
MAP2 is eluted at pH 8.6. Finally, a smaller amount of MAP2,
which remains bound to the iron-chelated column even at
pH 8.6, can be eluted together with the chelated iron after
washing with EDTA. The latter fraction presumably corresponds
to highly phosphorylated MAP2 which is strongly bound to the
iron-chelated column. To test if this is the case, i.c.a.c. was
performed with phosphatase-treated MAP2. A shift in the elution
ofMAP2 to lower pH values was observed. Most MAPs are now
eluted at pH 7.8-8.0 (Figure 6a, lower panel). This indicates that
the adsorption of MAP2 to the iron-chelated column indeed
depends on the phosphorylation level ofthe protein, as previously
demonstrated for other proteins [41,42]. Similar results were
obtained for MAP2 preparations from cow and rat brain.
Antibody 972 reacts much less readily with the MAP2 fraction
eluted from the i.c.a.c. column with EDTA than with the MAP2
fraction eluted at pH 7.8 (Figure 6b). No differences in the
immunoreactivities of the two MAP2 fractions toward antibody
10 were observed. Thus a fraction of purified MAP2 appears to
be highly phosphorylated (because of the strong adsorption to
the i.c.a.c. column) and one of its phosphorylated sites seems
to correspond to the site recognized by antibody 972 (because of
the weak reaction with this antibody).
In vivo phosphorylation state of MAP2 at the epitope recognized
by antibody 972 during rat brain development
To analyse the variation in phosphorylation at the site recognized
by antibody 972 during rat brain development, heat-resistant
cytosolic proteins from brains of rats of different ages were either
obtained in the presence of phosphatase inhibitors or were
previously treated with alkaline phosphatase. These fractions
were subjected to PAGE and analysed by Western-blot assay
with antibody 972.
Table 1 Degree of phosphorylation at the site recognized by antibody 972
on MAP2 throughout rat brain development
The fold increase in immunoreactivity for antibody 972 of MAP2A/B and MAP2C after
phosphatase treatment is shown. Data correspond to mean values + S.D. from three experiments
like the one shown in Figure 7 after densitometry of the corresponding autoradiograms. El 9,
Embryonic day 19; P1, postnatal day 1; P21, postnatal day 21.
Developmental Developmental
stages of Fold stages of Fold
MAP2C increase MAP2A/B increase
E19
P1
P21
2.3 + 0.7
2.1 + 0.6
0.8 + 0.3
El 9
P1
P21
1.3 + 0.2
1 +0.6
2.6 + 0.4
Figure 7 shows that antibody 972 reacts with both MAP2A/B
and MAP2C in these samples. Two extra protein bands are
recognized by antibody 972 in the preparation from 21-day-old
rat brain. These protein bands presumably correspond to pro-
teolytic fragments derived from MAP2A/B, as MAP2 proteolysis
increases with age [53]. Pretreatment with alkaline phosphatase
causes an increase in the electrophoretic mobility of MAP2C as
well as a sharpening of the protein band.
Pretreatment with alkaline phosphatase increases the immuno-
reactivity of MAP2C from embryonic and 1-day-old rat brain
toward antibody 972, without modifying the reaction of
MAP2A/B with this antibody. In -contrast, pretreatment with
alkaline phosphatase of the brain proteins from 21-day-old
rats results in an increase in the immunoreactivity of MAP2A/B
with antibody 972, without any significant change in the reaction
of MAP2C. No differences in immunoreactivity were observed
with antibody 660 which reacts with phosphorylation-indepen-
dent epitopes on MAP2A/B and MAP2C. The quantification of
these results is presented in Table 1. A large increase in the
;: ::g
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reaction of the protein with antibody 972 after the pretreatment
with alkaline phosphatase may indicate a high degree of
phosphorylation of the protein at the region reacting with
antibody 972. Accordingly, it appears that MAP2C is more
phosphorylated at the site recognized by antibody 972 during
early rat brain development, whereas it is essentially
dephosphorylated at this site by 21 days after birth. In contrast,
MAP2A/B seems to be more phosphorylated at this site in the
adult rat brain.
The phosphorylated state of MAP2C can therefore be
correlated with the time of axonal growth. In fact, MAP2C has
been localized to growing axons in developing neurons [54,55].
Other MAPs are highly phosphorylated at the time of axonal
growth. These include MAPIB [38,56-59] and tau [60-65].
Furthermore, some phosphorylated isoforms of these proteins
have been specifically localized to growing axons in immuno-
cytochemical studies [56-59,63-66]. More interestingly, all these
phosphorylation events have been mapped to Ser/Thr-Pro motifs
and are supposed to be catalysed by proline-directed protein
kinases. Here we suggest that the phosphorylation of embryonic
MAP2C at the epitope for antibody 972 may be included in this
scheme. Thus there seems to be phosphorylation of several
cytoskeletal proteins including MAP1B, MAP2C and tau by
proline-directed protein kinases which is specifically associated
with the growth of axons. This may be related to the maintenance
of a highly dynamic cytoskeletal organization that is competent
for rapid axonal growth. In fact, this type of phosphorylation is
reduced at the time of axonal maturation, presumably to stabilize
the axonal cytoskeleton [62,66].
The presence of MAP2A/B phosphorylated at the epitope for
antibody 972 in the adult rat brain is consistent wtih previous
reports showing a significant degree of phosphorylation in MAP2
isolated from adult rat brain [25,26,31]. MAP2A/B is specifically
localized to neuronal cell bodies, dendrites and dendritic spines
[8-12]. Phosphorylation and dephosphorylation of MAP2 at
these locations may lead to transient postsynaptic cytoskeletal
disassembly and reassembly which might contribute to different
forms of synaptic plasticity [1,30,32,34].
The fact that MAP2C and MAP2A/B are found maximally
phosphorylated at the epitope for antibody 972 at distinct
developmental stages (and also possibly at different cellular
locations) may indicate that different proline-directed protein
kinases are implicated in their phosphorylation. Several proline-
directed protein kinases show overlapping substrate specificities
[48,49,67] and may play a role in this respect. These include
cyclin-dependent kinases such as cdc2 [68,69], cdk4 [70] and cdk5
[70-72], as well as MAP kinases such as p44 MAP kinase
(ERKI) and p42 MAP kinase (ERK2) [73,74]. Of particular
interest is the fact that p42 MAP kinase seems to be co-localized
with MAP2 on dendrites in mature neurons [73]. Furthermore,
this enzyme has a high affinity for MAP2 with a Km of 56 nM
[75]. Interestingly, membrane depolarization results in both MAP
kinase activation [76] and increased MAP2 phosphorylation [30].
As p42 MAP kinase can be activated in response to certain
neurotransmitters [77,78], this enzyme should be considered a
candidate for the regulation of MAP2 phosphorylation and
cytoskeletal rearrangements in dendrites.
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